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Abstract
Germanium has long been considered a therapeutic agent with anticancer, antitumor, anti-
aging, antiviral and anti-inflammatory effects. Numerous clinical studies have explored the
promising therapeutic effects of organic germanium on cancer, arthritis and senile osteopo-
rosis. The immune activation property of organic germanium is considered the foundation of
its various therapeutic effects. However, previous human clinical studies investigating
immune activation with organic germanium compounds have certain limitations, as some
studies did not strictly follow a randomized, double-blind, placebo-controlled design. To
build a more clinically substantiated foundation for the mechanism underlying its immunosti-
mulation, we structured by far the most rigorous clinical study to-date with a group of 130
human subjects to examine changes in immune profiles following germanium supplementa-
tion. We used Bio-Germanium, an organic germanium compound naturally synthesized via
a yeast fermentation process. An 8-week randomized, double-blind, placebo-controlled
study was conducted with 130 subjects with leukocyte counts of 4–8 (×103/μL) divided into
the Bio-Germanium group and the placebo group. Anthropometric measurements; blood
collection; biochemical analysis; urinalysis; and natural killer cell activity, cytokine and
immunoglobulin assays were conducted. Results showed the Bio-Germanium group exhib-
ited NK cell activity increases at effector cell:target cell (E:T) ratios of 50:1, 10:1, 5:1 and
2.5:1 (12.60±32.91%, 10.19±23.88%, 9.28±16.49% and 7.27±15.28%, respectively), but
the placebo group showed decreases (P<0.01). The difference in the IgG1 change from
baseline to follow-up between the Bio-Germanium and placebo groups was significant (P =
0.044). Our results and earlier clinical study of Bio-Germanium confirm that Bio-Germanium
acts as an effective immunostimulant by increasing the cytotoxicity of NK cells and activat-
ing immunoglobulin, B cells and tumor necrosis factor (TNF)-α (P<0.05). As we have added
newly discovered clinical findings for germanium’s immunostimulation mechanism, we
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Germanium is a naturally occurring ultratrace element with a wide application range, from
the electronics industry to the dietary supplement industry [1, 2]. Organic germanium has
been reported to be a therapeutic agent with anticancer [3], antitumor [4, 5], antiaging [6, 7],
antiviral [8] and anti-inflammatory [9, 10] effects; its anticancer and antiviral effects have been
observed in vivo, and its antitumor, antiaging and anti-inflammatory effects have been
observed both in vivo and in vitro. In addition, organic germanium compounds have been
effective in treating cancer and arthritis [11, 12] and in enhancing immune function [13–15]
in pathological conditions in preclinical studies.
Numerous clinical studies have explored the promising therapeutic effects of organic ger-
manium on disease. Human clinical trials in lung cancer have revealed that organic germa-
nium supplementation benefited survival, tumor regression and overall improvements in
performance status and immunological parameters [16]. Other clinical investigations have
demonstrated the preventive and therapeutic effects of organic germanium on senile osteopo-
rosis through the enhancement of osteoblast activity [17]. In cancer patients especially, organic
germanium ameliorated side effects from chemotherapy and radiotherapy [18]; lowered the
rates of cancer metastasis and recurrence [18]; prolonged the survival and relieved the pain of
terminal cancer patients [19]; and resulted in partial and complete remission of cancer [20,
21].
Generally, the immune activation property of organic germanium is deemed to be the foun-
dation of its various therapeutic effects, such as anticancer, antiaging, antiviral and anti-
inflammatory effects—areas in which immune function plays a key role. In preclinical studies,
germanium’s immune activation was observed in a wide spectrum of immune system func-
tions, evidenced by the activation of NK cells, T cells, macrophages, neutrophils, lymphokines,
and interferons [15, 22–25]. In clinical studies, significant immunostimulatory effects were
shown by the activation of NK cells, macrophages, and neutrophils in patients taking organic
germanium [26–28].
Despite the abundance of studies in the literature, we believe previous human clinical stud-
ies of immune activation with organic germanium compounds have certain limitations, as
some studies did not strictly follow a randomized, double-blind, placebo-controlled design. To
build a more clinically substantiated foundation for the mechanism behind its immunostimu-
lation, we believe a large-scale human clinical study is needed to bridge the gap between pre-
clinical and clinical results. For this reason, we structured by far the most rigorous clinical
study to-date with a group of 130 human subjects to examine changes in immune profiles fol-
lowing 8 weeks of germanium supplementation. Additionally, instead of designing targeted,
disease-specific research, we chose healthy human subjects in the ages between 20 and 75 with
normal immune function to establish a more universal basis so that the immune activation
mechanism of germanium would have wider application.
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We used Bio-Germanium, a naturally synthesized organic germanium, for our clinical trial.
Bio-Germanium was developed in the late 1980s in the search for safer and more natural
organic germanium. This new type of organic germanium is formulated by a natural yeast cul-
tivation process, containing stable organic germanium bound to yeast protein [29–31]. Bio-
Germanium has been subjected to various safety [1, 32–36] and efficacy [2, 10, 37–39] analyses
and has been sold on the market for over 20 years. In addition, Bio-Germanium is acknowl-
edged as a new dietary ingredient by the US Food and Drug Administration (FDA, ID: FDA-
2010-S-0665-0243) and has been approved as a functional ingredient for immune enhance-
ment by the Korea Ministry of Food and Drug Safety (KMFDS, Functional Ingredient No.
2007–15). Furthermore, Bio-Germanium has been granted green list status by the US FDA
and is exempted from the import alert of germanium products (FDA Import Alert 54–07).
Our results and earlier clinical study of Bio-Germanium [38] confirm that Bio-Germanium
acts as an effective immunostimulant by increasing the cytotoxicity of NK cells and activating
immunoglobulin, B cells and tumor necrosis factor (TNF)-α (P<0.05). We have added newly
discovered clinical findings for germanium’s immunostimulation mechanism, substantiated
through a large-scale trial offering a universal basis by focusing on healthy human subjects.
We believe Bio-Germanium is a highly promising therapeutic agent and should certainly be
further explored for potential development opportunities in immunotherapy.
Materials and methods
History of germanium supplements
Germanium-containing dietary supplements became popular in the 1970s in Japan, in the
mid-1980s in Great Britain, and later in other countries [40]. However, due to a lack of aware-
ness of the danger of consuming inorganic minerals, certain fatalities occurred due to the
intake of inorganic germanium [40]. This is understandable because metal-based anticancer
drugs, such as cisplatin, carboplatin and oxaliplatin, started to be widely used at that time for
chemotherapy, and their side effects, such as nephrotoxicity, nausea, neurotoxicity, myopathy,
bone marrow suppression, renal failure and metal intoxication, were considered inevitable
parts of the chemotherapy and were generally tolerated for the purpose of cancer treatment, as
remission of cancer took priority over side effects. As some considered germanium to be a
new candidate amongst metal-based agents for chemotherapy, the behavior of continuing
long-term intake of even inorganic germanium formulation could have been influenced by
this notion of acceptance of side effects in desperation for treatment, subsequently resulting in
those fatalities. At any rate, the importance of an organic formulation was revisited [41], and
no such incidents of taking inorganic germanium have occurred since; currently, only organic
germanium is widely used. In the search for safer and more natural organic germanium, a new
type of organic germanium product, Bio-Germanium, was developed via germanium biosyn-
thesis utilizing a natural yeast cultivation process [42]. As yeast are known to detoxify toxic
metals and inorganic elements [43] through biological assimilation [37], yeast metabolic pro-
cesses are utilized to convert inorganic germanium into an organic compound. The safety of
Bio-Germanium has been extensively and thoroughly tested in in vitro, in vivo and human
clinical studies [1, 32–36, 38], and its efficacy has been assessed in the areas of immunostimula-
tion, antitumor effects, anti-inflammation and others [2, 10, 37–39].
Manufacturing bio-germanium
Bio-Germanium, our study material, was manufactured and provided by Geranti Pharmaceu-
tical. This new type of organic germanium is formulated via germanium biosynthesis, utilizing
a natural yeast cultivation process to enhance the biological activity and reduce the toxicity of
PLOS ONE Immune activation of Bio-Germanium in a clinical trial with 130 subjects: Insights and opportunities
PLOS ONE | https://doi.org/10.1371/journal.pone.0240358 October 19, 2020 3 / 22
inorganic elements. A reported advantage of trace element-concentrated yeast is the decreased
toxicity of the inorganic elements [44]. Additionally, microorganisms were found to convert
inorganic germanium into self-organizing germanium via self-accumulation; this method was
confirmed as a detoxification method [45]. Yeast, such as Saccharomyces cerevisiae, are known
to be harmless microorganisms in the human body and to play an important role as a medium
for comprehensive biological research in various fields, including molecular biology and
molecular genetics [46, 47]. The strain used for Bio-Germanium production was an S. cerevi-
siae strain (Korean Collection for Type Cultures, KCTC-7904, indexed as KCTC-1199 for-
merly) obtained from the Korea Research Institute of Bioscience and Biotechnology Gene
Bank.
Safety of bio-germanium
Bio-Germanium has been comprehensively tested for safety, with investigations ranging from
its organic structure, oral toxicity, and genotoxicity to its effects when consumed by humans.
Previous in vitro studies have confirmed that Bio-Germanium contains only organic germa-
nium by verifying that the germanium in Bio-Germanium is protein-bound organic germa-
nium; the inorganic form of germanium is not present in Bio-Germanium; and the
germanium in Bio-Germanium does not dissociate from yeast by dissolution in either gastric
juice or water [29–31]. Genotoxicity studies, such as reverse mutation, chromosomal aberra-
tion and micronucleus tests, indicated that Bio-Germanium neither causes mutagenic activity
nor possesses genotoxic potential [33]. In in vivo studies, acute (single, 14 days), subchronic
(repeated, 13 weeks) and chronic (10 consecutive months) oral toxicity studies were conducted
in both rats and beagle dogs, and Bio-Germanium was shown to be safe in animal studies at
dosages of 2000, 3000 and 5000 mg/kg body weight/day [1, 32, 34, 36]. Additionally, the accu-
mulation of Bio-Germanium, particularly in the kidneys and liver, was tested; those studies
showed that Bio-Germanium does not result in germanium accumulation in these organs
[35]. In human studies, organic germanium compounds are known to be well absorbed and
completely excreted from the body within 72 h [48–51]. Moreover, in a previous human clini-
cal trial of Bio-Germanium conducted in 50 subjects with an 8-week, randomized, double-
blind, placebo-controlled design, Bio-Germanium did not cause any adverse effects and, par-
ticularly, did not influence liver- and kidney-related biochemical markers, such as alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), creatinine, blood urea nitrogen
(BUN), total bilirubin (TB), and alkaline phosphatase (ALP), or anemia-related biochemical
markers, such as hemoglobin, hematocrit, and red blood cell count, after supplementation,
reconfirming its safety for human consumption [38]. Thus, through various in vitro, in vivo
and human clinical studies conducted previously, the study material, Bio-Germanium, was
confirmed to be a safe organic germanium suitable for consumption.
Efficacy of bio-germanium
Bio-Germanium has demonstrated efficacy in areas such as promoting immunostimulation,
inhibiting tumor progression, and conferring anti-inflammatory effects. In a study by Lee
et al. [38], Bio-Germanium demonstrated its immunostimulatory effect on humans through
the activation of tumor necrosis factor (TNF)-α and B cells (CD19) when compared with the
control group. As TNF-α is involved in the regulation of immune cells, such as in macrophage
phagocytosis and T cell homeostasis, and B cells function in adaptive immunity by secreting
antibodies, although more in-depth assessments of the responses of antigen-specific cytotoxic
lymphocytes and antibody responses to proteins and polysaccharide antigens are warranted,
Bio-Germanium seems to promote stimulation in both humoral and cell-mediated immunity.
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In a test of the anticancer and antitumor activities of Bio-Germanium by Baek et al. [2], sar-
coma-180 tumor-bearing C57BL/6 mice were fed plain yeast (S. cerevisiae) in the negative con-
trol group, doxorubicin (chemotherapy drug) in the positive control group, and Bio-
Germanium in the test group. In this study, Bio-Germanium treatment significantly reduced
the tumor weight in sarcoma-180 tumor-bearing mice, suggesting that the suppressed progres-
sion of tumors may have been the result of increased TNF-α production and effector function
of NK cells. Interestingly, while the doxorubicin group showed significant body weight loss,
the Bio-Germanium group did not exhibit a weight decrease. In addition to this antitumor
effect, the anti-inflammatory effect of Bio-Germanium against paw edema was investigated by
Lee et al. [10]. Male Sprague-Dawley rats (180–200 g) were injected with 100 μL of 1% carra-
geenan to induce paw edema. Ibuprofen (nonsteroidal anti-inflammatory drug) was used as a
positive control, and Bio-Germanium was applied in different concentrations as test treat-
ments. Ibuprofen significantly inhibited carrageenan-induced edema, and Bio-Germanium
also showed comparable inhibitory effects in a dose-dependent manner. Further study showed
that the anti-inflammatory activity of Bio-Germanium appears to be related to the inhibition
of arachidonic acid release and prostaglandin E2 (PGE2) production in rat basophilic leukemia
cells (RBL-2H3).
Organic properties of bio-germanium
A number of studies were conducted to determine the organic structure and properties of Bio-
Germanium, primarily prepared for the KMFDS approval application for a dietary ingredient
with immune enhancement function. The organic properties of Bio-Germanium were ana-
lyzed in the following steps: (1) its germanium-binding structure was investigated to determine
whether the germanium in Bio-Germanium is a protein-bound germanium by conducting ion
exchange chromatography and gel filtration to compare the elution profiles of plain yeast, ger-
manium dioxide and Bio-Germanium, and by conducting sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and N-terminal amino acid sequence analyses to
identify its protein type [29]; (2) the natural formulation technology via germanium biosyn-
thesis was assessed to determine whether the inorganic form of germanium is fully trans-
formed into an organic form by conducting X-ray diffraction (XRD), nuclear magnetic
resonance (NMR) and Fourier transform infrared spectroscopy (FT-IR) analyses to compare
the structural formation of plain yeast, germanium dioxide and Bio-Germanium [30]; (3) the
integrity of the organic conversion was investigated to ensure that no inorganic germanium is
present in Bio-Germanium by following a qualitative analysis protocol utilizing the unique
chemical properties of NaBH4 and GeO2 reactions, and NMR, ultraviolet visible spectropho-
tometry (UV-VIS), inductively coupled plasma atomic emission spectroscopy (ICP-AES),
FT-IR and XRD analyses were conducted to detect the presence of inorganic germanium in
Bio-Germanium [31]; and (4) the protein-bound germanium structure and its stability were
tested to determine the possibility of dissociation in gastric juice by applying dialysis mem-
brane tubing with a size cut-off of 1200 daltons to Bio-Germanium dissolved in simulated gas-
tric juice and assessing the presence of inorganic germanium [30]. In conclusion, Bio-
Germanium is confirmed to be a protein-bound organic germanium with a stable structure
and to not have any inorganic germanium present.
Study subjects and recruitment criteria
The current study enrolled 130 healthy subjects with leukocyte counts of 4–8 (×103/μL), which
is considered to be in the normal range for healthy humans. We screened volunteers recruited
from advertisements by the Clinical Nutrigenetics/Nutrigenomics Laboratory at Yonsei
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University. Adult male and female participants aged 20 years to 75 years with leukocyte counts
of 4–8 (×103/μL) were eligible for inclusion. The exclusion criteria were as follows: the con-
sumption of drugs or dietary supplements related to immune function within two weeks prior
to screening; an allergy to the study products and related substances; hypertension; diabetes;
any history/presence of significant metabolic disease; any history/presence of acute or chronic
infection of the liver, kidney, or gastrointestinal system; and any history/presence of any other
acute or chronic disease requiring treatment.
To recruit subjects with normal immune function, we used leukocyte counts because leuko-
cytes play important roles in immune responses and defense mechanisms [52, 53]. Normal leu-
kocyte counts are within a range of 4 to 10 (×103/μL) [54]. Leukocyte counts of less than 4
(×103/μL) are considered abnormal, and this status is diagnosed as leukopenia [55]. Con-
versely, Tamakoshi et al. reported that the relative risk (RR) of cardiovascular disease mortality
in patients with leukocyte counts of 8 to 10 (×103/μL) was more than twofold greater than that
in patients with leukocyte counts of 4 to 7.9 (×103/μL) (RR = 2.18, 95% confidence interval:
1.23–3.88) [56]. In addition, many studies have revealed that an elevated leukocyte level in
blood circulation and vessel walls is a predictive indicator of inflammation [57–60]. Therefore,
within the normal range of 4 to 10 (×103/μL), a slightly decreased upper range of 4 to 8 (×103/
μL) was defined. The fasting whole blood leukocyte counts of the volunteers were measured,
and 130 participants who met the inclusion criteria were ultimately enrolled. The purpose of
the study was carefully explained to all subjects, and written informed consent was obtained
before participation.
Registration of the clinical trial
The study protocol was approved on December 14th, 2017 by the Institutional Review Board of
Yonsei University (IRB No. 7001988-201712-HR-322) according to the Declaration of Hel-
sinki. Our clinical trial was first registered in the Clinical Research Information Service
(CRIS), which is an online clinical trial registration system established by the Korea Centers
for Disease Control and Prevention (KCDC) with support from the Korea Ministry of Health
and Welfare (KMOHW) and embodied as a part of the Primary Registries in the World Health
Organization (WHO) Registry Network. We registered our clinical trial in CRIS on January
19th, 2018 (https://cris.nih.go.kr—Identifier: KCT0002726). The first participant was enrolled
on January 9th, 2018, and the last (130th) participant’s final visit ended on June 5th, 2018. A gap
of ten days between the enrollment of the first participant and the trial registration dates
occurred due to logistical issues caused by earlier-than-expected inflow of screening candi-
dates for trial participation. To increase the global exposure of our trial, despite redundancy,
we also registered our trial in ClinicalTrials.gov on September 12th, 2018 (https://clinicaltrials.
gov—Identifier: NCT03677921). The authors confirm that all ongoing and related trials associ-
ated with this study material are registered.
Study design and determination of group size
An 8-week, randomized, double-blind, placebo-controlled clinical study was conducted with
130 subjects with leukocyte counts of 4–8 (×103/μL) who were divided into two groups: the
Bio-Germanium (test) group and the placebo (control) group. Over the eight-week testing
period, participants in the test group consumed 1200 mg of Bio-Germanium daily, while those
in the control group consumed placebo in the same amount. The sample size was determined
and calculated by reference to the NK cell cytotoxic activity results from another clinical trial
that showed statistically significant results [61]. According to the superiority test based on that
reference study, the delta (change) in the NK cell cytotoxic activity at an effector cell:target cell
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(E:T) ratio of 10:1 was -0.28±10.7% (mean ± standard deviation) in the placebo group and
lower than that in the test group (7.4±10.0%). Based on the difference in deltas between the
test and placebo groups (7.68), the application of a 75% adjustment based on the study’s rele-
vance in clinical efficacy yielded an effect size (d) of 5.76. The sample size was then determined
via a two-sample t-test power calculation with an effect size (d) of 5.76, a power of 0.8, and a
level of significance (α) of 0.05. The result indicated that a minimum of 55 subjects per group
was needed, and we estimated a dropout ratio of 15%; thus, we selected 65 participants to
increase the statistical power of the test.
Study material information and compliance
In this human clinical trial, Bio-Germanium was used at a dosage of 1200 mg/day for 8 weeks
in accordance with the approval from KMFDS. According to the blinded and randomized allo-
cation schedule, the participants received Bio-Germanium or placebo in individual bottles,
and both the test and placebo products were provided as capsules and were identical in pack-
aging, appearance, color, texture, and smell. The participants were instructed to consume 4
capsules per day: 2 capsules after breakfast and 2 capsules after dinner. Hydroxypropyl methyl-
cellulose (HPMC) capsules were used to encapsulate the test and placebo ingredients. The
study material information is as follows (Table 1):
Compliance was assessed by counting the remaining capsules and food records. If more
than 70% of the capsules were consumed, the compliance was considered fulfilled.
Implementation of the clinical trial
This study was designed as a randomized, double-blind, placebo-controlled clinical trial. Via
computer-generated block randomization lists (the randomization program of SAS version
9.4; SAS Institute, Cary, North Carolina, USA), 130 participants were randomly assigned to
receive either placebo or Bio-Germanium. A third-party expert randomly coded the blinded
allocation schedule and strictly controlled the double-blind conditions. The principal investi-
gators enrolled participants and allocated subjects according to the given blinded allocation
schedule. Those assigned to the test group received Bio-Germanium, and those assigned to the
control group received corn starch as placebo. Corn starch was chosen as it is conventionally
used as placebo in human trials involving immune experiments [62, 63]. Participants, health-
care providers, investigators, outcome assessors and data analysts were kept blinded
Table 1. Study material information.
Bio-Germanium Placebo
Criteria Information Criteria Information
Capsule Material White HPMC capsule Capsule Material White HPMC capsule
Capsule Size Size #1 capsule (300 mg) Capsule Size Size #1 capsule (300 mg)
Capsule Filling Powder form Capsule Filling Powder form
Dosage Guidance 4 capsules per day (1200 mg/day) Dosage Guidance 4 capsules per day (1200 mg/day)
Main Ingredient Bio-Germanium (100%) Main Ingredient Corn starch (96.7%)
Appearance Powder in light brown color Color Additive 1 Brown (2.0%)
Flavor Slightly pungent, soybean smell Color Additive 2 Yellow (0.4%)
KMFDS Approval Functional ingredient with immune enhancement function Color Additive 3 Red (0.4%)
Color Additive 4 Green (0.1%)
KMFDS Approval No. No. 2007–15 Flavor Additive 1 Soybean paste (0.3%)
KMFDS Guidance 1200 mg/day Flavor Additive 2 Grain powder (0.1%)
https://doi.org/10.1371/journal.pone.0240358.t001
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throughout the process. Unblinding did not occur during the clinical trial. The code opening
of the allocation schedule for statistical analysis occurred only after the blinded data review
was complete. The overall clinical trial management and monitoring, database design and con-
struction, data entry and validation, statistical analysis, and final report documentation were
performed by an external contract research organization.
Anthropometric parameters and blood collection
The body weight, fat percentage (UM0703581; Tanita, Tokyo, Japan) and height (GL-150; G-
tech International, Uijeongbu, Korea) of the subjects were measured in the morning, with the
subjects wearing lightweight clothes and no shoes; body mass index (BMI) was then calculated
in units of kilograms per square meter (kg/m2). Systolic and diastolic blood pressure (BP) was
measured on the left arm using an automatic BP monitor (FT-200S; Jawon Medical, Gyeong-
san, Korea) after a 20-min rest. The participants were instructed to not smoke or drink alcohol
for at least 30 min before the BP measurement and fast for 12 h before the blood sample collec-
tion, which was conducted at the following check points: screening, week 0, week 4 and the
final follow-up visit on week 8. The blood samples were also used to conduct routine checkups
and detect any sign of acute conditions. Venous blood specimens were collected in EDTA-
coated and plain tubes and were then centrifuged to yield plasma and serum, respectively,
which were stored at -70˚C until analysis.
Preparation for and execution of the cytotoxicity assay
After the blood collection, to prepare for the isolation of the peripheral blood mononuclear
cells (PBMCs) to be used as effector cells, the whole blood sample was immediately mixed with
the same volume of RPMI 1640 medium (Gibco22400-089; Thermo Fisher Scientific, Wal-
tham, Massachusetts, USA), gently overlaid on Histopaque1 (1077; Sigma-Aldrich, Irvine,
UK) and centrifuged for 20 min at 1800 rpm and 15˚C. After the separation, the buffy coat
layer was isolated, washed once with RPMI 1640 medium, and resuspended in 1 mL of 10%
FBS medium (fetal bovine serum; Cat.#16000–044; Gibco, Thermo Fisher Scientific, Waltham,
Massachusetts, USA) diluted with RPMI 1640. An automated cell counter (LUNA-II; Logos
Biosystems, Anyang, Korea) was used to identify and count the live cells among the PBMCs,
which completed the effector cell preparation for the assay. Human myeloid leukemia cells
(K562; Korean Cell Line Bank, KCLB No. 10243; Korean Cell Line Research Foundation,
Seoul, Korea) were used because these cells are highly sensitive and receptive in vitro target of
NK cells. Bottled and frozen K562 was withdrawn from the liquid nitrogen tank and immedi-
ately defrosted in a 37˚C water bath for 10 min. The defrosted K562 was transferred into a con-
ical tube containing 10% FBS medium. The cells were centrifuged, collected, resuspended in
fresh FBS medium and distributed into Erlenmeyer flasks ready for cultivation. K562 was cul-
tured in an incubator at 37˚C under 5% CO2, and its medium was replaced every 3 days along
with regular monitoring to detect any abnormality in morphological changes and cell spher-
oids. After confirming that K562 reached the log phase, which usually occurred within approx-
imately one week with its peak density approximating 0.75 million/mL, the target cells were
centrifuged and collected for the cytotoxicity assay. After completing the preparations of both
the effector and target cells for the cytotoxicity assay, the isolated PBMCs (E) were seeded into
96-well plates with K562 cells (T) at E:T ratios of 50:1, 10:1, 5:1 and 2.5:1 and incubated at
37˚C under 5% CO2 for at least 4 h. The cytolytic activities of NK cells were analyzed via the
CytoTox 961Non-Radioactive Cytotoxicity Assay Kit (G1782; Promega Co., Fitchburg, Mas-
sachusetts, USA) according to the manufacturer’s instructions. The color reactions were read
at 490 nm using the Victor X5 2030 multilabel plate reader (Victor X5 2030–0050;
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PerkinElmer, Hopkinton, Massachusetts, USA), and the results were calculated by the follow-
ing formula:
% Cytotoxicity ¼ ðExperimental‐Effector Spontaneous‐Target SpontaneousÞ=
ðTarget Maximum‐Target SpontaneousÞ � 100
We adhered to the official guidelines published by KMFDS regarding evaluating NK cell
cytotoxicity and the assay kit manufacturer’s instructions regarding using colorimetric meth-
odology. The assays were performed on-site on the same day as the blood collection under ran-
domized and double-blinded conditions, and the obtained assay results were kept blinded
until the code open. The PBMCs were used as a whole without the isolation of NK cells and
discarded without storage after the analyses were completed.
Biochemical and biomarker assays
Hematological analysis was performed using a HORIBA ABX automated blood counting ana-
lyzer (HORIBA ABX Micro ES60; HORIBA Ltd., Tokyo, Japan). Serum glucose concentra-
tions were measured according to the hexokinase method on a Hitachi 7600 autoanalyzer
(Hitachi 7600 Modular; Hitachi Group, Tokyo, Japan). Serum albumin concentrations were
analyzed through the bromocresol green (BCG) method using an ALB kit (DCA Vantage Ana-
lyzer; SIEMENS, Tarrytown, New York, USA) with an ADVIA 2400 autoanalyzer (ADVIA
2400 Chemistry System; SIEMENS, Tarrytown, New York, USA). Leukocyte counts were
determined using the HORIBA ABX diagnostic analyzer (HORIBA ABX Micro ES60; HOR-
IBA Ltd., Tokyo, Japan). ALT and AST levels were measured by the International Federation
of Clinical Chemistry and Laboratory Medicine (IFCC) UV method using a Hitachi 7600 auto-
matic analyzer (Hitachi 7600 Modular; Hitachi Ltd, Tokyo, Japan). The URiSCAN system
(URiSCAN 10 SGL Strip; YD Diagnostics, Yong-In, Korea) was used to evaluate urine speci-
mens for the diagnosis of renal diseases and systemic adverse effects. The urine specimens
were analyzed for specific gravity, pH, leukocyte count, nitrite, protein, glucose, ketones, uro-
bilinogen, bilirubin, and occult blood. Immunoglobulin (Ig) G1, IgG2 and IgM were measured
by the immune nontuberculous method using a Bep II instrument (BEP 2000 Advance System;
SIEMENS, Tarrytown, New York, USA).
Statistical analysis
For the general characteristics and survey results, noncontinuous variables are presented as
numerical values and percentages, whereas continuous variables are presented as averages and
means ± standard deviations or ± standard errors. Analyses were performed using a per-proto-
col approach. All data were analyzed using SAS1 (Version 9.4; SAS Institute, Cary, North
Carolina, USA). The Kolmogorov-Smirnov test was used to test normality. The Wilcoxon
signed-rank test (for skewed variables) and independent t-tests (for normally distributed vari-
ables) were used to compare parameters between the control (placebo) and test (Bio-Germa-
nium) groups. Chi-square tests were used for categorical variables. ANCOVA was used to
adjust the baseline values for further comparison. Comparisons between the baseline measure-
ments and the measurements collected at follow-up visits for each group were performed via
paired t-tests. A two-tailed P-value of less than 0.05 was considered statistically significant.
Results
Our clinical trial discovered novel findings for the mechanism of germanium immunostimula-
tion in the human body by revealing the increased cytotoxicity of NK cells and activation of
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IgG1. The final results of this study included 128 subjects, excluding one subject who voluntar-
ily dropped out and one who had poor compliance (less than 70%). No adverse events were
observed during the clinical trial. The first participant was enrolled on January 9th, 2018, and
the last (130th) participant’s final visit ended on June 5th, 2018. A flow diagram of the randomi-
zation of subjects is presented in Fig 1.
Basic characteristics of the subjects
Table 2 outlines the basic baseline characteristics of the two groups. At baseline, there were no
significant differences between the two groups in age, sex distribution, weight, BP, exercise sta-
tus, family history, and the ratio of smokers/alcohol drinkers. We used the leukocyte count as
the subject inclusion criterion for normal immune function, and significant differences were
not found at baseline between the two groups. The Bio-Germanium group recorded 5.38±1.06
(×103/μL), while the placebo group recorded 5.52±1.02 (×103/μL) as baseline leukocyte counts
(P>0.05).
Natural killer cell cytotoxicity and immunoglobulin values
NK cell cytotoxic activities (%) were measured based on E:T ratios of 50:1, 10:1, 5:1 and 2.5:1.
As outlined in Table 2, profound differences between the two groups were found in NK cell
cytotoxicity at all E:T ratios (50:1 to 2.5:1) at follow-up. The NK cell cytotoxic activities in the
Bio-Germanium group at E:T ratios of 50:1, 10:1, 5:1 and 2.5:1 were significantly higher than
those in the placebo group at follow-up (P<0.05) with respect to the baseline values (Table 3).
When we compared the changes in the two groups (Fig 2), the Bio-Germanium group
exhibited NK cell cytotoxicity increases at E:T ratios of 50:1, 10:1, 5:1 and 2.5:1 (12.60±32.91%,
10.19±23.88%, 9.28±16.49% and 7.27±15.28%, respectively), but the placebo group showed
decreases (P<0.01). Notably, the Bio-Germanium group with an E:T ratio of 2.5:1 exhibited a
near twofold increase from 8.91% at baseline to 16.19% at follow-up. The sub-analyses of the
Fig 1. Flow diagram of subject randomization. 1 Completed the clinical trial without major protocol violations.
https://doi.org/10.1371/journal.pone.0240358.g001
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female subjects categorized into the pre- and post-menopause groups are provided in the S1
File.
For immunoglobulins, the difference in the IgG1 change from baseline to follow-up
between the placebo group (-2079.03±5006.03 mg/dL) and the Bio-Germanium group
(-275.76±4996.28 mg/dL) was statistically significant (P = 0.044, Table 4).
Although the changes from baseline to follow-up between the placebo and test groups for
IgG2 (-1860.63±5286.78 mg/dL, -366.67±2953.09 mg/dL, respectively) and IgM (-0.13±9.44
mg/dL, 2.47±7.83 mg/dL, respectively) did not show statistically significant differences with P-
values less than 0.05 (P = 0.076 for IgG2 and P = 0.092 for IgM), the trends in the IgG2 and
Table 2. Basic characteristics and anthropometric values of the subjects at baseline.
Total Subjects (n = 128) Placebo Group (n = 62) Bio-Germanium Group (n = 66)
Baseline Baseline Baseline P
Male / Female n, (%) 13(10.16) / 115(89.84) 4(6.45) / 58(93.55) 9(13.64) / 57(86.36) 0.179
Age (year) 53.64 ± 11.08 53.31 ± 10.67 53.95 ± 11.53 0.742
Weight (kg) 60.87 ± 9.40 60.86 ± 10.18 60.88 ± 8.68 0.989
Height (cm) 159.20 ± 6.21 158.85 ± 6.18 159.53 ± 6.26 0.539
Leukocyte counts (×103/μL) 5.45 ± 1.04 5.52 ± 1.02 5.38 ± 1.06 0.427
Systolic BP (mmHg) 115.90 ± 12.32 115.53 ± 12.95 116.24 ± 11.78 0.746
Diastolic BP (mmHg) 70.48 ± 8.54 70.16 ± 8.96 70.77 ± 8.19 0.687
Current smoker n, (%) 3 (2.34) 0 (0.00) 3 (4.55) 0.2451
Current drinker n, (%) 43 (33.59) 18 (29.03) 25 (37.88) 0.110
Exercise +3 times per week n, (%) 64 (50.00) 29 (46.77) 35 (53.03) 0.771
Family history of immune disease n, (%) 0 (0.00) 0 (0.00) 0 (0.00) -
The data represent subject count, percentage and the mean ± standard deviation at baseline.
P-values were derived from a chi-square test (noncontinuous variables) or independent t-test (continuous variables).
1 Derived from Fisher’s exact test.
- Not applicable.
https://doi.org/10.1371/journal.pone.0240358.t002
Table 3. NK cell cytotoxicity values at baseline and follow-up.
Placebo Group (n = 62) Bio-Germanium Group (n = 66)
(%) Baseline Follow-up Baseline Follow-up Pa Pb Pc
E:T = 50:1 49.44 ± 25.53 46.01 ± 24.57 43.27 ± 8.44 55.87 ± 27.85�� 0.125 0.011
Δ -3.44 ± 27.01 12.60 ± 32.91 0.007
E:T = 10:1 29.79 ± 17.42 24.67 ± 15.17� 23.33 ± 20.54 33.52 ± 17.50��� 0.006 0.002
Δ -5.12 ± 18.30 10.19 ± 23.88 <0.001
E:T = 5:1 20.65 ± 13.66 14.06 ± 10.05�� 14.01 ± 10.86 23.29 ± 14.91��� 0.003 <0.001
Δ -6.59 ± 16.27 9.28 ± 16.49 <0.001
E:T = 2.5:1 14.05 ± 16.19 9.20 ± 8.82� 8.91 ± 10.49 16.19 ± 12.44��� 0.020 <0.001
Δ -4.86 ± 18.23 7.27 ± 15.28 <0.001
The data represent the mean ± standard deviation.
Δ represents the change from baseline at follow-up.
Pa-values were derived from the Wilcoxon rank-sum test at baseline between groups.
Pb-values were derived from the Wilcoxon rank-sum test at follow-up between groups.
Pc-values were derived from adjusted baseline ANCOVA for Δ between groups.
�P<0.05, ��P<0.01 and ���P<0.001 values were derived from a paired t-test at follow-up from baseline within groups.
https://doi.org/10.1371/journal.pone.0240358.t003
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IgM variations were similar to that of IgG1 (Fig 3), with the Bio-Germanium group exhibiting
a better performance than the placebo group.
Anthropometric, biochemical and urinary analysis of the safety set
Based on the safety set with 130 subjects, anthropometric, biochemical and urinary analyses
were performed under the intention-to-treat (ITT) principle in a set of subjects who received
the product and completed at least one safety evaluation [64, 65]. The anthropometric and bio-
chemical data revealed no abnormal findings (Tables 5 and 6). General characteristics of blood
composition observed in white blood cells, red blood cells, hemoglobin, hematocrit, and
Fig 2. Comparison of NK cell cytotoxicity Δ values before and after supplementation. The data represent the
mean ± standard error. Δ represents the change from baseline at follow-up. ��P<0.01 and ���P<0.001 values were
derived from adjusted baseline ANCOVA for Δ between groups.
https://doi.org/10.1371/journal.pone.0240358.g002
Table 4. Immunoglobulin G1, G2 and M values at baseline and follow-up.
Placebo Group (n = 62) Bio-Germanium Group (n = 66)
(mg/dL) Baseline Follow-up Baseline Follow-up Pa Pb Pc
IgG1 82804.84 ± 15720.12 80725.81 ± 14306.39�� 79272.73 ± 15087.10 78996.97 ± 16327.15 0.197 0.396
Δ -2079.03 ± 5006.03 -275.76 ± 4996.28 0.044
IgG2 47364.52 ± 18764.35 45503.89 ± 18729.89�� 43692.42 ± 18349.00 43325.76 ± 17725.25 0.269 0.412
Δ -1860.63 ± 5286.78 -366.67 ± 2953.09 0.076
IgM 114.76 ± 63.12 114.63 ± 63.27 109.68 ± 62.41 112.15 ± 62.81� 0.691 0.858
Δ -0.13 ± 9.44 2.47 ± 7.83 0.092
The data represent the mean ± standard deviation.
Δ represents the change from baseline at follow-up.
Pa-values were derived from an independent t-test (IgG1, normally distributed) or the Wilcoxon rank-sum test (IgG2 and IgM, not normally distributed) at baseline
between groups.
Pb-values were derived from the Wilcoxon rank-sum test at follow-up between groups.
Pc-values were derived from an independent t-test (IgG1 and IgM, normally distributed) or the Wilcoxon rank-sum test (IgG2, not normally distributed) for Δ between
groups.
�P<0.05 and ��P<0.01 values were derived from a paired t-test at follow-up from baseline within groups.
https://doi.org/10.1371/journal.pone.0240358.t004
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platelets showed no significant differences after supplementation between the test and placebo
groups. Additionally, none of the biochemical parameters, including AST, ALT, total protein,
glucose, total cholesterol, BUN, creatinine, uric acid and others, showed significant
differences.
In particular, no significant differences in the changes in liver- and kidney-related bio-
chemical markers, such as AST, ALT, creatinine, BUN and uric acid, after supplementation
were found between the test and placebo groups. In addition, the results of urinary analyses of
all subjects in the Bio-Germanium group were normal (Table 7).
As adverse events were not observed during our clinical trial in conjunction with the sup-
porting results from these anthropometric, biochemical and urinary analyses, the safety of Bio-
Germanium for human consumption, which has been supported by earlier preclinical and
clinical studies as well as by the over 20-year-long history of safe use, was also revalidated by
our clinical trial.
Discussion
The novel findings of this randomized, double-blind, placebo-controlled study indicated that
the immunostimulation mechanism of Bio-Germanium is associated with the activation of
NK cells and immunoglobulin.
Compared with the placebo group, the Bio-Germanium group showed significantly greater
increases in NK cell activity at E:T ratios of 50:1, 10:1, 5:1, and 2.5:1. The immunostimulatory
Fig 3. Comparison of immunoglobulin G1, G2 and M Δ values before and after supplementation. The data
represent the mean ± standard error. Δ represents the change from baseline at follow-up. �P<0.05 value was derived
from an independent t-test for Δ between groups.
https://doi.org/10.1371/journal.pone.0240358.g003
Table 5. Anthropometric data of the subjects (safety set).
Placebo Group (n = 64) Bio-Germanium Group (n = 66)
Baseline Follow-up1 Δ Baseline Follow-up Δ P
Systolic BP (mmHg) 115.53 ± 12.78 114.73 ± 12.69 -0.71 ± 10.18 116.24 ± 11.78 116.35 ± 13.14 0.11 ± 11.47 0.669
Diastolic BP (mmHg) 70.20 ± 8.83 70.11 ± 8.99 -0.03 ± 8.09 70.77 ± 8.19 71.06 ± 9.18 0.29 ± 8.32 0.825
Heart Rate (bpm) 77.41 ± 8.68 78.06 ± 9.44 0.75 ± 8.11 77.08 ± 10.58 75.77 ± 10.14 -1.30 ± 8.71 0.170
Body Temperature (˚C) 36.20 ± 0.16 36.13 ± 0.14 -0.07 ± 0.19 36.20 ± 0.16 36.14 ± 0.14 -0.05 ± 0.21 0.633
Weight (kg) 61.08 ± 10.17 60.71 ± 10.41 -0.14 ± 1.13 60.88 ± 8.68 60.92 ± 8.72 0.04 ± 1.03 0.340
The data represent the mean ± standard deviation.
Δ represents the change from baseline at follow-up.
P-values were derived from an independent t-test for Δ between groups.
1 Safety set analysis of the placebo group at follow-up consisted of 63 participants, excluding one subject’s voluntary dropout.
https://doi.org/10.1371/journal.pone.0240358.t005
PLOS ONE Immune activation of Bio-Germanium in a clinical trial with 130 subjects: Insights and opportunities
PLOS ONE | https://doi.org/10.1371/journal.pone.0240358 October 19, 2020 13 / 22
capability found in our study shows that Bio-Germanium augmented NK cell activity, one of
the key markers of immune strength [66–68]. Additionally, the change in IgG1 from the base-
line level was significantly different between the Bio-Germanium group and the placebo
group.
Table 6. Biochemical data of the subjects (safety set).
Placebo Group (n = 64) Bio-Germanium Group (n = 66)
Baseline Follow-up1 Δ Baseline Follow-up Δ P
White Blood Cell (×103/μL) 5.53 ± 1.01 5.47 ± 1.39 -0.05 ± 1.33 5.38 ± 1.06 5.17 ± 1.15 -0.21 ± 1.22 0.483
Red Blood Cell (×106/μL) 4.62 ± 0.66 4.72 ± 0.69 0.10 ± 0.85 4.62 ± 0.58 4.78 ± 0.77 0.15 ± 0.93 0.733
Hemoglobin (g/dL) 13.50 ± 1.36 13.70 ± 1.89 0.20 ± 1.72 13.69 ± 1.84 13.99 ± 2.25 0.30 ± 2.59 0.805
Hematocrit (%) 41.94 ± 6.13 42.63 ± 6.30 0.70 ± 7.86 41.96 ± 5.47 43.33 ± 7.47 1.37 ± 8.61 0.647
Platelet (×103/mm3) 251.81 ± 63.92 225.79 ± 52.22 -25.38 ± 52.96 239.17 ± 57.83 220.68 ± 50.76 -18.48 ± 62.81 0.502
Lymphocyte (×103/mm3) 1.96 ± 0.47 1.90 ± 0.51 -0.05 ± 0.41 1.97 ± 0.54 1.86 ± 0.48 -0.11 ± 0.36 0.413
Monocyte (×103/mm3) 0.18 ± 0.07 0.17 ± 0.08 -0.01 ± 0.09 0.19 ± 0.09 0.17 ± 0.07 -0.02 ± 0.09 0.416
AST (IU/L) 23.52 ± 7.95 21.38 ± 6.96 -1.57 ± 3.84 22.59 ± 6.52 21.12 ± 5.60 -1.47 ± 4.17 0.886
ALT (IU/L) 20.31 ± 13.97 18.86 ± 13.01 -0.70 ± 6.37 19.68 ± 9.09 18.48 ± 7.69 -1.20 ± 4.68 0.615
Total Protein (g/dL) 7.34 ± 0.35 7.50 ± 0.33 0.17 ± 0.33 7.32 ± 0.36 7.48 ± 0.35 0.16 ± 0.31 0.913
Glucose (mg/dL) 90.89 ± 10.64 92.49 ± 11.67 1.68 ± 8.02 88.61 ± 10.18 91.82 ± 10.14 3.21 ± 7.00 0.250
Total Cholesterol (mg/dL) 194.86 ± 39.98 205.95 ± 42.67 10.13 ± 22.85 194.70 ± 38.31 201.68 ± 38.36 6.98 ± 18.24 0.389
BUN (mg/dL) 14.48 ± 3.78 14.44 ± 3.62 -0.08 ± 3.30 14.53 ± 0.18 14.56 ± 3.44 0.03 ± 2.87 0.841
Creatinine (mg/dL) 0.69 ± 0.14 0.66 ± 0.12 -0.03 ± 0.09 0.71 ± 0.16 0.69 ± 0.16 -0.02 ± 0.10 0.576
Uric acid (mg/dL) 4.57 ± 1.20 4.61 ± 1.08 0.03 ± 0.70 4.48 ± 1.03 4.58 ± 1.09 0.10 ± 0.65 0.575
Ca (mg/dL) 9.36 ± 0.37 9.40 ± 0.33 0.03 ± 0.39 9.38 ± 0.35 9.39 ± 0.28 0.01 ± 0.33 0.778
P (mg/dL) 3.80 ± 0.47 3.84 ± 0.49 0.03 ± 0.45 3.77 ± 0.44 3.86 ± 0.43 0.09 ± 0.33 0.375
The data represent the mean ± standard deviation.
Δ represents the change from baseline at follow-up.
P-values were derived from an independent t-test for Δ between groups.
1 Safety set analysis of the placebo group at follow-up consisted of 63 participants, excluding one subject’s voluntary dropout.
https://doi.org/10.1371/journal.pone.0240358.t006
Table 7. Urinary analysis data of the subjects (safety set).
Placebo Group (n = 63)1 Bio-Germanium Group (n = 66)
Normal Results Abnormal Findings Normal Results Abnormal Findings P
Specific Gravity n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
pH n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Protein n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Glucose n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Ketone n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Bilirubin n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Urobilinogen n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Nitrite n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Leukocyte n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
Erythrocyte n, (%) 63 (100.0) 0 (0.0) 66 (100.0) 0 (0.0) -
The data represent results at follow-up.
1 Safety set analysis of the placebo group at follow-up consisted of 63 participants, excluding one subject’s voluntary dropout.
- Not applicable.
https://doi.org/10.1371/journal.pone.0240358.t007
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This result is consistent with that of a previous clinical study showing the immunostimula-
tory effect of Bio-Germanium in humans. Lee et al. [38] reported that in fifty human subjects
ranging in age from 50 to 75 years, B cell (CD19) activity and TNF-α production were
increased in the Bio-Germanium group, as indicated by flow cytometric analysis using a
monoclonal antibody and by TNF-α enzyme immunometric assay. Similarly, our findings are
consistent with those of previous in vivo studies. Joo et al. [39] conducted a plaque-forming
cell (PFC) assay and evaluated the effect on antibody production in mice fed Bio-Germanium.
This study also showed that the proliferation of B cell subset compositions increased in a dose-
dependent manner, from 48.9% (100 mg/kg) to 50.1% (200 mg/kg) to 53.2% (400 mg/kg) to
55.6% (800 mg/kg), and that the PFC count also increased. Another study by Baek et al. [2]
showed that the administration of Bio-Germanium induced nitric oxide production and
increased superoxide anion release, thereby increasing phagocytosis, macrophage activation
and TNF-α production. Most importantly, NK cell-mediated cytotoxicity was also increased
in a dose-dependent manner in their in vivo study, a result revalidated by our clinical study.
As NK cells are partly activated in response to macrophage-derived cytokines [69], our
hypothesis to focus on the NK cell profile in this study largely originated from the macrophage
activations observed in these in vivo studies. Moreover, the emerging importance of NK cells
in maintaining general health as well as in defending against malignant diseases, as revealed in
various studies, has shown that NK cells are one of the key components in the protective func-
tion of the immune system and that the cytotoxicity of NK cells is one of the key indicators of
immune system activation. Fundamentally, NK cell effector function has been recognized as a
primary contributor to innate immunity in viral, bacterial and parasitic infections and as a cru-
cial regulator for the initiation of the adaptive immune response [70]. NK cells can also con-
tribute to protective responses against a variety of inflammatory pathologies and even cancers
[71–73]. Furthermore, the cytotoxic activity of NK cells was used as a cancer prognostic
marker in an 11-year follow-up study to predict the probability of future development of can-
cer, revealing that medium and high cytotoxic activity could reduce the relative risk of cancer
incidence [74]. Additionally, well-preserved NK cytotoxicity can be considered a marker of
healthy aging, while low NK cytotoxicity is a predictor of increased morbidity and mortality
due to infections [75]. Integrating the above findings with the previous studies of Bio-Germa-
nium, we developed our hypothesis that the prevailing mechanism of the immunostimulatory
function of germanium is based on NK cells. Subsequently, our clinical results substantiated
that the immunostimulatory capability of germanium supplementation was associated with
augmented NK cell cytotoxicity.
Generally, the immunostimulation property of organic germanium is deemed to be the
foundation of its various therapeutic effects, such as anticancer, antiaging, antiviral and anti-
inflammatory effects—areas in which immune function plays a key role. The immune function
activation mechanism of organic germanium is established by enriching the oxygen supply
[48, 76, 77], detoxifying heavy metal elements [48, 78–80], scavenging reactive oxygen species
(ROS) [81–83] and increasing reduced glutathione (GSH) levels [81, 84]. El-Din [85] reported
that organic germanium showed radical scavenging activity immediately after tumor inocula-
tion and γ-irradiation exposure, resulting in the suppression of tumor growth and in the
reduction of cellular injury from γ-irradiation-induced toxicity, which were attributable to the
inhibition of the cascade reaction of membrane lipid peroxidation. This finding is important
because oxidative stress and the overproduction of ROS have been associated with the patho-
genesis of tumors and cancer [86]. Additionally, Pronai and Arimori [87] reported that super-
oxide scavenging activity in patients with certain immunological disorders was significantly
lower than that in healthy controls. Interestingly, the scavenging function of organic germa-
nium has been observed on several different types of ROS, such as hydrogen peroxide,
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superoxide anion, and hydroxyl radicals [7, 88, 89]. As supplementation of antioxidants
decreases the level of oxidative stress by their ROS-scavenging activities and thereby helps
maintain GSH at high levels [90], the scavenging activities of organic germanium can also
explain its role in increasing GSH levels. In fact, GSH plays an important role in enhancing
immune function [91]. Increasing the GSH concentration in relevant tissues elicits an antitu-
mor effect by stimulating immunity through the GSH pathway [92], while GSH depletion sta-
tus can lead to decreased lymphocyte proliferation and impaired macrophage and T cell
function [93]. Collectively, scavenging ROS and increasing GSH levels by organic germanium
can be deemed the founding mechanism for its immunostimulation and immune
enhancement.
Finally, to our knowledge, this study is the first to examine immunoglobulin levels after ger-
manium intervention in human subjects. IgG1 is the major serum immunoglobulin and is
principally responsible for the recognition, neutralization, and elimination of pathogens and
toxic antigens [94], and the activation of NK cells increases the IgG1 level and facilitates the
production of IgG2a antibodies in the in vivo setting [95]. As the affinity of an immunoglobu-
lin for an antigen is utilized to enhance immune effector functions [96] and hypofucosylated
IgG1 and IgG3 enhance the effector functions of NK cells [97], the discovery of IgG activation
in relation to the activation of NK cells by Bio-Germanium in a clinical setting is considered a
novel finding of this study. Additionally, Bio-Germanium’s activation of B cells (CD19) in
humans was confirmed earlier by Lee et al. [38], which was deemed appropriate as CD19
serves as a signaling intermediary for the stimulation of CD86 on B cells, effecting the subse-
quent involvement of CD86 in the regulation of the IgG1 levels [98].
Because the humoral immunity component is activated by the secretion of antibodies, such
as IgG, and the cell-mediated immunity component is activated by antigen-specific cytotoxic
lymphocytes, we can suggest further exploration to identify future opportunities in the applica-
tion of Bio-Germanium in B cell and T cell combined therapies. However, as our current
study did not focus on investigating the activities of antibodies, more research in this area is
warranted in the future. Even though this randomized placebo-controlled study clearly showed
that supplementation with Bio-Germanium conferred the immunostimulatory effect, the pri-
mary focus of this study was on investigating the working mechanism behind Bio-Germani-
um’s immunostimulation, not on investigating the specificity of effect on a particular disease.
To initiate its drug discovery process, further investigation is required in areas such as disease-
specific mechanisms and patient-specific effects.
We have also noticed that certain differences in findings from various studies exist due to
dissimilarities between experimental tests and clinical trials, including subject selection. Our
subjects were healthy adult volunteers between 20 and 75 years of age with normal immune
function, while most previous studies were conducted with cancer patients or in in vivo set-
tings; thus, the subjects’ physiological and general environmental conditions should also be
considered. In particular, some immune parameters were decreased at follow-up in both the
control and test groups. Our research was carried out from January 9th to June 5th, and as most
subjects were tested during the winter and spring, the immune-related parameters were possi-
bly affected by the cold, windy weather in the winter [99] and Asian Dust (AD) outbreaks dur-
ing the spring in Seoul. Regarding sudden temperature changes, Brenner et al. reported that
cold exposure can contribute to deteriorations in immune function, including a reduction in
the NK cell count [100]. In Seoul, the daily average temperature in January and February was
below 0˚C (32˚F), and the lowest temperature was -18˚C (0˚F). The temperature abruptly
increased to 22˚C (72˚F) in mid-March, decreased again to 0˚C (32˚F) in early April, and then
surged to 26˚C (79˚F) in mid-April [101]. Such abrupt undulation of temperature within a
short duration could be regarded quite extraordinary. In addition, AD, originating from the
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deserts and drylands of Mongolia, affects Korea from March to May. One study noted that AD
particles can alter immune response profiles [102]. The severe weather conditions and AD in
Seoul during the trial period may have had a certain impact on our baseline differences and
the declining trends observed in certain parameters in both the placebo and test groups.
Last but not least, if our study had not been bound by time and resource constraints, more
immediate and frequent observations in the earlier stage of the immunocytokine changes,
cytokine secretion assays in response to certain stimuli in selected immune cells from isolated
PBMCs and additional exhaustive observations of NK cells during their isolation from PBMCs
would have allowed us to capture a more holistic picture of the immunostimulation mecha-
nism of Bio-Germanium as immunocytokine changes are sometimes instantaneous and short-
lived. Also, to better understand the influence of Bio-Germanium on the antibody immune
response, further evaluation of the activities of antigen-specific cytotoxic lymphocytes and the
responses of antibodies to certain proteins and polysaccharide antigens are imperative to eluci-
date its mechanism in humoral immunity. Additionally, the use of clinical data from a single
center, the imbalance in the male and female proportion, and the disproportional age distribu-
tion could be limitations, and caution is needed in generalizing these results to a broader
population.
In conclusion, this clinical trial confirms that Bio-Germanium supplementation stimulates
immune function by increasing the cytotoxicity of NK cells and activating immunoglobulin, in
addition to activating B cells and TNF-α, as observed in an earlier clinical study [38]. We have
added newly discovered clinical findings for germanium’s immunostimulation mechanism
substantiated through a large-scale trial offering a universal basis by focusing on healthy
human subjects, and have contributed to bridging the gap between preclinical and clinical
results. We believe Bio-Germanium is a highly promising therapeutic agent and should cer-
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